Abstract

Phasing agents enabling de novo protein structure determination at ca. 1 Å, the wavelength corresponding to the maximum intensity of the synchrotron facilities applied in biomacromolecular crystallography, have been long sought-after. The first phasing agent designed for solving native protein structures at 0.97934 Å is described herein. The agent consists of a neutral ytterbium(III)-caged complex that exhibits higher anomalous signals at shorter wavelengths when compared to the best, currently applied lanthanide-based phasing agents, all of them based on gadolinium or terbium. As a proof of principle, the complex allows determining the 3D structure of a 36 kDa protein without setting the incident beam wavelength at the metal absorption edge, the strategy followed to date to gain the strongest anomalous signal even at the expense of crystallographic resolution. The agent becomes nondisruptive to the diffraction quality of the marked crystals and allows determining accurate phases, both leading to high-quality electron-density maps that enable the full tracing of the protein structure only with one agent unit bound to the protein. The high phasing power, efficient binding to the protein, low metal-macromolecule ratio, and easy handling support the developed Yb(III) complex as the best phasing agent for X-ray crystallography of a complex biomacromolecule without using modified analogues.

Highlights

  • Nowadays, X-ray crystallography is the most successful technique for determining the 3D structure of proteins and other biomacromolecules, which is essential for advances in biomedicine

  • The most popular phasing agents used for this valuable purpose present important drawbacks, mainly related with the lack of generality when applied to different protein crystals, low solubility in the mother liquor in which the protein crystallizes or is soaked, low intrinsic efficiency for producing the required anomalous signalization, and/or low efficiency for a proper heavy-atom derivatization.[17]

  • Www.acsabm.org biomacromolecule crystallography; (2) using a tricarboxylbased clathrochelating ligand to build up a neutral, Yb(III)caged complex, which should be endowed with both the wellknown chemical stability of the caged lanthanide complexes[39] and hydrophobicity sufficient to efficiently bind to common, accessible protein hydrophobic pockets, that is, without requiring occupancy or vacancy at the binding metal center to increase the efficiency of the binding to the protein; (3) involving a reactive peripheral functionalizing group to achieve further chemical modulation of the phasing agent,[38] if required, for example, to improve the solubility in the aqueous crystals of the mother liquor,[47] or for linking a fluorescent tag to discern marked versus unmarked crystals,[43] or a biorecognition moiety for specific protein binding;[48] and (4) synthetic accessibility

Read more

Summary

Introduction

X-ray crystallography is the most successful technique for determining the 3D structure of proteins and other biomacromolecules, which is essential for advances in biomedicine. The most popular phasing agents used for this valuable purpose (e.g., gold,[5] bromine, iodine,[6−10] certain metallic salts,[11−13] polymetallic clusters,[14,15] or heavy noble gases16) present important drawbacks, mainly related with the lack of generality when applied to different protein crystals, low solubility in the mother liquor in which the protein crystallizes or is soaked, low intrinsic efficiency for producing the required anomalous signalization, and/or low efficiency for a proper heavy-atom derivatization (e.g., low ratio of structure-distorting heavy atoms per macromolecule unit).[17]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call